DNA Therapeutics is funded by venture capital (SEFTI), institutional seed (G1J Ile-de-France, Inserm-Transfert Initiative) investors, and business angels located in France, in Europe, and in China. The company has also received various public supports for innovation from the French government and EU, as R&D grants, subsidies, and no-interest loans. Since its foundation, 12 million euros have been consumed in R&D activities and enabled the achievement of clinical proof of concept.

For the next clinical development to demonstrate systemic antitumor activity and improve the standard of care in the treatment of resistant cancers, the company is looking for 12-15 million euro funding.